Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial.

American journal of respiratory and critical care medicine - 1 Aug 2026

Okuda Ryo, Nishioka Yasuhiko, Kondoh Yasuhiro, Tsubouchi Kazuya, Okamoto Masaki, Nishiyama Osamu, Sato Seidai, Oishi Keiji, Ishikawa Nobuhisa, Chiba Hirofumi, Miyazaki Yasunari, Homma Sakae, Ogura Takashi, Inoue Yoshikazu, Azuma Arata

Abstract excerpt

RATIONALE: No recommended therapy exists for chronic fibrosing interstitial lung diseases (CF-ILDs) with disease progression despite ongoing treatment with nintedanib or pirfenidone. Pamufetinib (also known as TAS-115) is a novel oral antifibrotic tyrosine kinase inhibitor in development for CF-ILD with a progressive phenotype. OBJECTIVE: We sought to evaluate the dose-response of pamufetinib monotherapy in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Disease
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Idiopathic Pulmonary Fibrosis

Share to Indoles

Share to Lung Diseases, Interstitial

Share to Protein Kinase Inhibitors

Share to Pyridones

Share to Vital Capacity

Source

Open in PubMed Open full text

Identifiers

PMID: 42085242
DOI: 10.1093/ajrccm/aamag125
PMCID: PMC13424673

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial.PMID 42085242Read ↗

Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies.Semantic proximity Read ↗

Progressive fibrotic interstitial lung disease.Semantic proximity Read ↗

The progressive fibrotic phenotype in current clinical practice.Semantic proximity Read ↗

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.Semantic proximity Read ↗

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis.Semantic proximity Read ↗

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).Semantic proximity Read ↗

Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype.Semantic proximity Read ↗

An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?Semantic proximity Read ↗

Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.Semantic proximity Read ↗

A syndromic framework for progressive pulmonary fibrosis.Semantic proximity Read ↗

Progressive fibrosing interstitial lung disease: prevalence and clinical outcome.Semantic proximity Read ↗

Clinical features of idiopathic pleuroparenchymal fibroelastosis with progressive phenotype showing a decline in forced vital capacity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.